315 studies found for:    "Multiple Sclerosis, Relapsing-Remitting"
Show Display Options
RSS Create an RSS feed from your search for:
"Multiple Sclerosis, Relapsing-Remitting"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Terminated
Has Results
Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Minocycline;   Drug: Placebo
2 Completed An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention:
3 Active, not recruiting Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: GSK239512;   Drug: Placebo
4 Completed A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Rebif®;   Drug: Avonex®
5 Unknown 
Has Results
A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: interferon beta-1a (Rebif®);   Biological: alemtuzumab
6 Completed
Has Results
A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Rebif® New Formulation (IFN-beta-1a, RNF);   Drug: Placebo
7 Unknown  Melatonin in Relapsing-Remitting Multiple Sclerosis Patients
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Melatonin
8 Recruiting Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention:
9 Withdrawn QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)
10 Not yet recruiting Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: RNS60 125 ml;   Drug: RNS60 250 ml;   Drug: Interferon beta 1a
11 Completed
Has Results
A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Cladribine 5.25 mg/kg;   Drug: Cladribine 3.5 mg/kg;   Other: Placebo
12 Completed Safety and Efficacy Study of Daclizumab High Yield Process to Treat Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-remitting
Interventions: Biological: Daclizumab High Yield Process;   Other: placebo
13 Terminated Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis
Condition: Relapsing-remitting Multiple Sclerosis
Intervention: Drug: Interferon beta-1b
14 Active, not recruiting Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
Conditions: Relapsing Remitting Multiple Sclerosis;   Autoimmune Diseases;   Immune System Diseases;   Nervous System Diseases;   Autoimmune Diseases of the Nervous System
Intervention: Drug: BAF312
15 Recruiting Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)
Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Drug: RHB-104
16 Completed
Has Results
Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Interferon beta 1b (Betaseron, BAY86-5046)
17 Terminated A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Part A: 100 mg/mL GSK2618960;   Drug: Part A: matching placebo;   Drug: Part B: Dose of GSK2618960 decided from Part A;   Drug: Part B: matching placebo;   Drug: Part C: Dose of GSK2618960 decided from Part A and B
18 Terminated
Has Results
Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod
Condition: Relapsing Remitting Multiple Sclerosis (RRMS)
Interventions: Drug: Fingolimod;   Drug: Placebo
19 Active, not recruiting A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: Glatiramer acetate (GA);   Other: Placebo
20 Completed A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects
Condition: Relapsing Remitting Multiple Sclerosis (RRMS)
Intervention: Device: RebiSmart

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years